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Introduction
 Prostate cancer (PC) is the most common solid tumor 
in men followed by lung and colon cancer in the western 
world and second most common cause of cancer death 
among men (Jemal et al., 2009; Hernes et al., 2010). Also, 
current treatments for advanced PC are limited. Several 
novel drugs have been designed to target specific pathways 
involved in PC development and progression. 
 Metformin is the most widely used anti-diabetic 
drug in the world, but there is increasing evidence of 
a potential efficacy of this agent as an anticancer drug 
recently. Epidemiological studies show a decrease 
in cancer incidence in metformin treated patients. In 
addition, metformin decreases insulin resistance and 
indirectly reduces insulin level, a beneficial effect as 
insulin promotes cancer cell growth. Several reports 
also outline a direct inhibitory effect of metformin on 
cancer cell growth and an antitumoral action. Recently, 
numerous studies have shown that metformin decreases 
cancer cell viability and tumor growth (Murtola et 
al., 2008; Wright et al., 2009; Libby et al., 2009). The 
potential for application of metformin in oncology was 
first recognized in retrospective epidemiological studies of 
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Abstract
 Background and Aims: Prostate cancer is the most commonly diagnosed cancer in males in many populations. 
Metformin is the most widely used anti-diabetic drug in the world, and there is increasing evidence of a potential 
efficacy of this agent as an anti-cancer drug. Metformin inhibits the proliferation of a range of cancer cells 
including prostate, colon, breast, ovarian, and glioma lines. MicroRNAs (miRNAs) are a class of small, non-
coding, single-stranded RNAs that downregulate gene expression. We aimed to evaluate the effects of metformin 
treatment on changes in miRNA expression in PC-3 cells, and possible associations with biological behaviour. 
Materials and Methods: Average cell viability and cytotoxic effects of metformin were investigated at 24 hour 
intervals for three days using the xCELLigence system. The IC50 dose of metformin in the PC-3 cells was found 
to be 5 mM. RNA samples were used for analysis using custom multi-species microarrays containing 1209 
probes covering 1221 human mature microRNAs present in miRBase 16.0 database. Results: Among the human 
miRNAs investigated by the arrays, 10 miRNAs were up-regulated and 12 miRNAs were down-regulated in the 
metformin-treated group as compared to the control group. In conclusion, expression changes in miRNAs of 
miR-146a, miR-100, miR-425, miR-193a-3p and, miR-106b in metformin-treated cells may be important. This 
study may emphasize a new role of metformin on the regulation of miRNAs in prostate cancer. 
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diabetic patients with cancer. Several studies have reported 
decreased cancer incidence and cancer related mortality 
in diabetics receiving standard doses of metformin (1500-
2250 mg/day in adults) (Decensi et al., 2010; Landman 
et al., 2010). Metformin also displays significant growth 
inhibitory effects on several cancer cells. In cell culture, 
metformin inhibits the proliferation of a range of cancer 
cells including prostate, colon, breast, ovarian, and glioma 
(Isakovic et al., 2007; Gotlieb et al., 2008).
 MicroRNAs (miRNAs) are a class of small, non-
coding, single-stranded RNAs that negatively regulate 
gene expression by mainly binding to 3’ untranslated 
region (UTR) of target mRNAs at the post-transcriptional 
level. Recent studies have demonstrated that aberrant 
expressions of miRNAs are closely associated with the 
development, invasion, metastasis and prognosis of 
various cancers including PC. Regulations of the growth, 
differentiation and apoptosis of carcinoma cells controlled 
by the interaction of miRNAs with their target genes 
have been investigated recently (Iorio and Croce, 2009). 
The involvement of miRNAs in human PC has clearly 
demonstrated a correlation between miRNAs and their 
targets with prostate carcinogenesis in recent years (Shi, 
2007; Jemal, 2009). Several miRNAs and their targets 
Cigir Biray Avci et al
Asian Pacific Journal of Cancer Prevention, Vol 14, 2013766
have been discovered to get expressed abnormally in PC, 
leading to the corresponding response in the development, 
invasion, and metastasis of this disease. The altered 
expressions of some selected miRNAs are useful as 
biomarkers for diagnosis, prognosis, and classification 
purposes of PC (Porkka, 2007; Mattie, 2006). Thus, 
understanding of the characteristic miRNA abnormalities, 
and restoring normal miRNA-mRNA regulation pathways 
could contribute to the development of novel therapeutic 
strategies in PC.
 This study was undertaken to evaluate the effects of 
metformin treatment on the cellular miRNA expression 
changes in PC-3 prostate cancer cell line, and possible 
association of miRNAs and metformin on prostate cancer 
has been analyzed for the first time. Results may reveal 




Cell line, culture conditions and drug
 PC-3 (Androgen Independent Phenotype) prostate 
cancer cells were used as a model in this study which 
was obtained from ATCC. PC-3 cells were grown in 
RPMI-1640 Basal medium containing 2mM L-glutamine 
supplemented with 10% fetal bovine inactivated serum 
(FBS) and 1% penicillin/streptomycin in a standard cell 
culture incubator at 37oC, humidified 95% air, and 5% 
CO2 atmosphere. Metformin AICAR (Toronto Research 
Chemicals, Inc.) was dissolved in culture media.
Real-time xCELLigence impedance analysis of the 
cytotoxicity of metformin on PC-3 cells
 The real-time cell analyzer was used to evaluate cell 
survival, according to the supplier’s instructions. After 
seeding 200 microL of the cell suspensions into the 
wells (10,000 cells/well) of the E-plate 96, cells were 
treated with increasing concentrations of metformin and 
monitored every 15 minutes for 90 hours.
Statistical analysis of cytotoxicity
 Calculations of cytotoxicity were obtained by using 
the real-time cell analyzer integrated software, which 
performs a curve-fitting of selected “sigmoidal dose-
response equation” to the experimental data points. 
Data are represented as mean (mmol/L)±SD (n 5). For 
the statistical analyses of the proliferation experiments, 
one-way analysis of variance (ANOVA) and Tukey-
Kramer multiple comparison tests were used. The data 
are represented as means±standard deviations. A value 
of p<0.05 was considered to be statistically significant.
MicroRNA microarrays
 RNA samples were used for analysis using custom 
multi-species microarrays containing 1209 probes 
covering 1221 human mature microRNAs present in 
miRBase 16.0 database. The array also contains 1037 
probes covering 1052 mouse mature microRNAs, 679 
probes covering 680 rat mature microRNAs and 484 
probes covering 488 rhesus mature microRNAs. The 
sensitivity of the microarray is such that it could detect as 
low as 20 amoles of synthetic microRNA being hybridized 
along with each sample. The microarrays were produced 
by Microarrays Inc. (Huntsville, Alabama), and consisted 
of epoxide glass substrates that had been spotted in 
triplicate with each probe.
Sample processing 
 Quality of the total RNA samples was assessed using 
UV spectrophotometry and agarose gel electrophoresis. 
Low molecular weight (LMW) RNA (~0-200 nucleotides) 
was purified from total RNA by size fractionation on 
Nanosep 100K ultra-filtration columns (Pall Life Sciences, 
Ann Arbor, MI) and subsequent purification using the 
RNeasy MinElute Clean-Up Kit (Qiagen, Inc., Valencia, 
CA) using a small RNA Protocol. The LMW RNA 
samples were 3’-end labeled with Oyster-550 fluorescent 
dye using the Flash Tag RNA labeling Kit (Genisphere 
Inc., Hatfield, PA). Labeled LMW RNA samples were 
hybridized to the MicroRNA microarrays according to 
conditions recommended in the Flash Tag RNA labeling 
Kit manual. The microarrays were scanned on an Axon 
Genepix 4000B scanner, and data was extracted from 
images using GenePix V4.1 software.
Data pre-processing
 Spot intensities were obtained for the 8816 features 
on each microarray by subtracting the median local 
background from the median local foreground for each 
spot. Detection Thresholds for each array were determined 
by calculating the 10% trim mean intensity of the negative 
controls spots and adding 5X the standard deviation of the 
background (non-spot area). The spot intensities and the 
Threshold (T) were transformed by taking the log (base 
2) of each value. The normalization factor (N) for each 
microarray was determined by obtaining the 20% trim 
mean of the human probes intensities above threshold in 
all samples. The log2-transformed spot intensities for all 
8816 features were normalized, by subtracting N from 
each spot intensity, and scaled by adding the grand mean 
of N across all microarrays. The mean probe intensities 
for each of the 1209 human probes on each array were 
then determined by averaging the triplicate spot intensities. 
Spots flagged as poor quality during data extraction 
were omitted prior to averaging. The 1209 human non-
control log2-transformed, normalized, and averaged 
probe intensities were filtered to obtain a list of human 
microRNA probes showing probe intensity above T in at 
least 10% of the samples. 
Microarray quality control 
 Each array contains probes targeting 11 different 
synthetic miRNAs, each of which is added at a mass of 
200 amoles to each RNA sample prior to labeling and 
hybridization. Sensitivity of the microarray hybridization 
was confirmed by detection of hybridization signal for 
all 11 spikes well above the detection threshold. The 
array also contains a set of specificity control probes 
complementary to three different miRNAs. Each 
specificity control includes a perfect match, single 
mismatch, double mismatch, and shuffled version of the 
probe. Specificity of the hybridization was confirmed by 
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detection of hybridization signal on the microarray for 
the perfect match probes and not the double mismatch 
and shuffled version of the probes. Reproducibility of the 
arrays was determined by monitoring the hybridization 
intensity for the triplicate human spots on each array. 
The sensitivity, specificity, and reproducibility data for 
the arrays were compiled into a Quality Control report.
Differential expression analysis
 For statistical analysis, samples were binned into 
different treatment groups. The log2-transformed and 
normalized spot intensities for the detectable human 
probes were examined for differences between the different 
groups using the ANOVA module built into the National 
Institute of Ageing (NIA) Array Analysis software. The 
statistical significance was determined using the False 
Discovery Rate (FDR) method which was proposed by 
Benjamini and Hochberg (1995). It is the proportion of 
false positives among all probes with P values lower or 
equal to the P value of the probes that is considered to be 
significant. It can also be viewed as an equivalent of a 
P-value in experiments with multiple hypotheses testing. 
FDR is an intermediate method between the P-value and 
Bonferroni correction (multiplying P-value by the total 
number of probes). The equation is: where r is the rank of 
a probe ordered by increasing P values, pi is the P value 
for probe with rank i, and N is the total number of probes 
tested. FDR value increases monotonously with increasing 
P value. 
 Fold changes between treatment and control samples 
were computed and presented along with the log2 
transformed spot intensities of the detectable probes. 
For Principal Component Analysis (PCA), samples 
were binned into respective treatment groups. PCA was 
performed on the detectable probes using the module built 
in to the National Institute of Ageing (NIA) Array Analysis 
software (Sharov et al., 2005).
Hierarchical clustering of microRNA array data
 Data for the detectable human probes were clustered 
using Cluster 3.0 software (De Hoon et al., 2004). Genes 
were median centered prior to hierarchical clustering. 
Hierarchical clustering was conducted using Centered 
Correlation as the similarity metric and Average Linkage 
as the clustering method. Intensity scale shown is arbitrary.
Results 
 Evaluation of the expression profiles of miRNAs 
were analysed in PC-3 cells treated with 1-5 mM doses 
of metformin at 24, 48 and 72 h time intervals. miRNA 
expression analysis was performed and expression rates 
were detected in a time and dose dependent manner. 
Metformin exerts its cytotoxic effects on PC-3 cells in a 
time- and dose-dependent fashion. The relative reduction 
in the cell number that evolved in cultures of PC-3 cells 
was determined. These experiments aimed to assess 
the best concentration of metformin to be used in PC-3 
prostate cell line. A real-time cell analyzer (xCELLigence, 
Roche Applied Science, Mannheim, Germany) was used 
to evaluate cell survival after 24, 48 and, 72 h exposure 
to metformin, and the results were shown in Figure 1. 
The IC50 was found to be 5 mM revealed by Xcelligence 
system which was also confirmed by WST-1 assay.
miRNA expression profiles 
 Among the human miRNAs investigated by the arrays, 
10 miRNAs were up-regulated and 12 miRNAs were 




Prostate cancer is the most frequently diagnosed 
cancer in men and the second most common cause of 
cancer related death in the western world. A number 
of in vitro and in vivo studies have shown an effect of 
metformin on inhibiting the growth of multiple cancer cell 
lines including that of prostate cancer. Ben et al. (2008) 
showed that metformin gave an up to 50% decrease in 
cell viability in human prostate cancer cell lines including 
PC-3 cells (Ben et al, 2008). The potential mechanism 
of activity of metformin has not been completely 
understood. In an American population based case-control 
study, metformin usage was associated with a 44% risk 
reduction in prostate cancer incidence (Wright et al., 
2009). Evidence for metformin on cancer cell growth 
has been clearly established in a series of in vitro studies. 
Table 1. miRNA Alteration in Response to Metformin 
(Fold change>2-fold)























Figure 1. Proliferation of PC-3 Cells in Response to 
Metformin by X-celligence System
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Actually, metformin exposes a strong and consistent anti-
proliferative effect on several cancer cell lines including 
prostate, colon, pancreas, breast, and lung. Metformin is 
associated with a reduction of prostate cancer incidence, 
and also metformin inhibits human prostate cancer cells 
proliferation and tumor formation. At the cellular level, 
metformin interferes with cell cycle leading to G0/G1 or 
S phase arrest. Some studies suggested that metformin 
triggered a cell cycle arrest at the G0/G1 stage with a 
reduction in cyclin D1 levels in human prostate cancer 
cells in vitro (Ben et al., 2008; Wright et al., 2009). 
Studies on the relationship between miRNAs and PC 
only started in recent years (Schaefer et al., 2009) but there 
is increasing evidence that altered expression of specific 
miRNAs are involved in the development and progression 
of prostate cancer (Baranwal and Alahari, 2010). As 
the progression of PC is rather a multiple combination 
with changes of expression of oncogenes and tumor 
suppressors, discovery of miRNAs goes a step forward to 
provide a novel regulatory mechanism for PC. Numerous 
studies are still being undertaken to clarify the complicated 
interaction between the multiple miRNAs and multiple 
target mRNAs. Many miRNAs have been found to be up-
regulated in PC by miRNA expression profiling analysis. 
Overexpression of the oncomirs epigenetically silences the 
apoptosis related genes, and then induces tumor growth 
and metastasis. Loss of tumor suppressor miRNAs is 
another mechanism related to the progression of PC. Lin et 
al. analyzed eight down-regulated and three up-regulated 
miRNAs in PC tissues and cell lines, and found that miR-
146a, one of the eight down-regulated miRNAs, was 
dramatically expressed. Forced expression of miR-146a 
resulted in remarkably reduced cell migration, invasion, 
proliferation, anti-apoptosis and metastasis in PC-3 cells, 
suggesting that miR-146a acts as a tumor suppressor in PC 
(Lin, 2008). The microRNA-200 family, which is down-
regulated in PC, are a group of potential tumor suppressor 
miRNAs. PC-3 cells that have lost expression of miR-200 
and miR-141, display a mesenchymal phenotype due to 
aberrant methylated CpG island near the miR-200 and 
miR-141, leading to invasion and metastasis of cancer 
cells (Kong et al., 2009; Vrba et al., 2010).
Our results showed that metformin treatment led 
to altered expression of some cellular miRNAs shown 
in tables. Our data suggests that expression changes in 
miRNAs of miR-146a, miR-100, miR-425, miR-193a-
3p and miR-106b in metformin exposed cells may be 
important.
The preclinical and limited clinical evidence that is 
available coupled with the drug’s favorable safety profile 
and low cost, justifies the need to pursue its further 
investigation in prostate cancer and other malignancies. 
Coupled with the implementation of new preclinical 
models, clinical trials will integrate to the development 
and effective use of metformin as a potential anticancer 
therapy. This work may demonstrate a novel role of 
metformin on the regulation of miRNAs in prostate cancer.
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